Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis (Q43294210)

From Wikidata

Jump to navigation Jump to search

scientific article published in October 2009

Language	Label	Description	Also known as
English	Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis	scientific article published in October 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

steatohepatitis

0 references

1 reference

based on heuristic

inferred from title

insulin resistance

1 reference

based on heuristic

inferred from title

Amalia Gastaldelli

object named as

Amalia Gastaldelli

1

0 references

author name string

Stephen A Harrison

2

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Renata Belfort-Aguilar

3

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Lou Jean Hardies

4

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Bogdan Balas

5

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Steven Schenker

6

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

Kenneth Cusi

7

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

language of work or name

0 references

publication date

1 October 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

1087-1093

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Thiazolidinediones in NASH. An odd couple meant to be?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Recent advances in nonalcholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

The effect of pioglitazone on the liver: role of adiponectin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Mechanisms of Disease: hepatic steatosis in type 2 diabetes--pathogenesis and clinical relevance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Mitochondria in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

21 January 2018

Lessons from animal models of NASH

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23116

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.23116

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43294210&oldid=1985736244"